0000078003-20-000079.txt : 20201215 0000078003-20-000079.hdr.sgml : 20201215 20201215180347 ACCESSION NUMBER: 0000078003-20-000079 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39787 FILM NUMBER: 201390691 BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER NAME: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pfizer Ventures (US) LLC CENTRAL INDEX KEY: 0001776087 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39787 FILM NUMBER: 201390692 BUSINESS ADDRESS: STREET 1: 235 EAST 42ND STREET CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 235 EAST 42ND STREET CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioAtla, Inc. CENTRAL INDEX KEY: 0001826892 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851922320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11085 TORREYANA ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-558-0708 MAIL ADDRESS: STREET 1: 11085 TORREYANA ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 primary_doc.xml PRIMARY DOCUMENT X0206 3 2020-12-15 0 0001826892 BioAtla, Inc. BCAB 0000078003 PFIZER INC 235 E 42ND ST NEW YORK NY 10017 0 0 1 0 0001776087 Pfizer Ventures (US) LLC 235 EAST 42ND STREET NEW YORK NY 10017 0 0 1 0 Series D Convertible Preferred Stock Common Stock 2238090 I See Footnote 2 Each share of Series D Convertible Preferred Stock will automatically convert into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. These share numbers reflect the 1-for-13 reverse split of the Common Stock effected by the Issuer on December 2, 2020. The Series D Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc. Pfizer Inc. By: /s/Susan Grant, Assistant Secretary 2020-12-15 Pfizer Ventures (US) LLC By: /s/Susan Grant, Secretary 2020-12-15